WuXi Biologics WuXi AppTec is expected to provide world-class integrated biopharmace
WuXi Biologics is a subsidiary of the WuXi AppTec Group with branches in Wuxi, Shanghai and Suzhou. As a platform for innovative companies to realize their dream of developing new drugs, WuXi AppTec is expected to provide world-class integrated biopharmaceutical R&D and manufacturing services to more innovative biotech companies at home and abroad in the future, accelerating the process of bringing innovative biopharmaceuticals to market in China for the benefit of patients.
Bid for Molecular Tech in China's Early-Stage Cancer Detection Market
China, with a population of 1.4 billion, has one of the largest gene pools in the world. How does its DNA tech-based cancer detection industry look? Listed on Nasdaq in 2020, Genetron Holdings Limited (Genetron Health) is taking a leading role.
Sep 09, 2020 03:08 PM
ResearchReal Estate, Consumer Discretionary, Industrials
Tech for Global, Globalization Footprints of the Established and the New
ResearchConsumer Staples, Industrials, Financials
Low-Carbon Industry Expansion - Key Studies From Chinese Companies
WIM Presents Next 50 in Global Tech: Healthcare
In 2020, as COVID-19 spread around the world, people began to pay more attention to the healthcare industry. The crisis of the pandemic has led directly to significant changes in the healthcare industry across the globe.
Oct 29, 2020 11:00 AM
Black Swans and Breakthroughs: China's Top 50 Innovative Public Firms in 2020
In the times of crisis like COVID-19, even established companies risk falling due to the sudden drop in their income. By contrast, companies that cling to innovation may unlock more value as they fight against the challenges.
Oct 20, 2020 07:40 PM
- China Speed: Two COVID-19 Vaccines Recognized by WHO
- After China's BNR and GTH Hit Nasdaq, Pan-Cancer Detector GRAIL Eyes IPO
- More Room for the Medical Device Market to Grow in China
- Tong Ren Tang: Any Hope for this Purveyor of Centuries-Old Chinese Medicines?
- Modern Chinese Medicine Maker Tasly Pharmaceutical: An Old Stock in a New Package?